Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Investing Activities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Cash from Investing Activities for 4 consecutive years, with -$87000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 1640.0% to -$87000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$229000.0, a 69.63% decrease, with the full-year FY2025 number at -$229000.0, down 69.63% from a year prior.
  • Cash from Investing Activities was -$87000.0 for Q4 2025 at Phathom Pharmaceuticals, down from -$27000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$5000.0 in Q4 2024 to a low of -$939000.0 in Q3 2023.
  • A 4-year average of -$189937.5 and a median of -$77000.0 in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: soared 98.95% in 2024, then plummeted 1640.0% in 2025.
  • Phathom Pharmaceuticals' Cash from Investing Activities stood at -$412000.0 in 2022, then decreased by 15.29% to -$475000.0 in 2023, then skyrocketed by 98.95% to -$5000.0 in 2024, then tumbled by 1640.0% to -$87000.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Cash from Investing Activities are -$87000.0 (Q4 2025), -$27000.0 (Q3 2025), and -$97000.0 (Q2 2025).